Skip to main content

New Hope for Curing Allergic Asthma by Restoring Immune Tolerance

Currently, up to 9% of American adults suffer from chronic asthma*, and in 60% of these cases the asthma is attributable to allergy. 

In the United States alone, the number of people diagnosed with allergy will increase by more than a million a year by 2060.

Although this growing disease already affects nearly one adult in 20, there is no cure or treatment for allergic asthma. And it’s no different for the allergy that causes it. The only solutions available for allergic asthma sufferers are symptomatic remedies or demanding desensitization treatments. Both approaches have shown their limits. Patients and their families are looking for something better. The unmet need is truly considerable.

It’s for them that ANGANY is developing a totally new approach. It involves treating allergic asthma by reversing the underlying immune dynamics, restoring immune tolerance to the allergen in question.

ANGANY Develops Cutting-Edge Immunotherapy for Allergic Asthma

The new-generation biologics under development at ANGANY offer the prospect of previously unattainable safety and efficacy attributes in the treatment of allergic asthma. Affected individuals can now look forward to a new therapeutic solution that will enable them to develop a protective response against the precise cause of their allergy, and thus control allergic asthma.

Both genetic and external factors can promote an allergic response against a component, usually a protein, from a source such as pollen or cat glands. ANGANY’s approach is to present the specific component to be treated as a 3D structure that the immune system perceives as a threat. This redirects the immune response towards one of a protective nature, promoting the gradual elimination of the programmed allergic response.

Allergic Asthma

A silent pandemic

Asthma is a chronic inflammatory disorder of the airways affecting around 262 million people worldwide. The overall prevalence in the United States is 7.7%. Asthma is triggered by a combination of genetic and environmental factors, but in the majority of diagnoses, 60-80%, asthma is allergy-related.

Read more

About ANGANY

We're an innovative pharmaceutical company committed to improving the lives of people with asthma

ANGANY is a private, clinical-stage pharmaceutical company that has developed a proprietary therapeutic platform based on synthetic biology. Its self-adjuvant vector, the eBioparticle™, has demonstrated at preclinical level, in models using cells from allergic people, the possibility of reversing the immune dynamics at the source of allergic asthma. An initial clinical study (first-in-human) conducted at Imperial College London showed remarkable results in terms of the safety of the ANG101 therapeutic candidate developed in the treatment of allergic asthma due to cat allergy. ANGANY has also developed a 3rd generation plant production platform that is flexible, fast and easy to scale-up.

Read more

Our Technology

ANGANY introduces a new approach to the treatment of allergic asthma

Its technology is the fruit of over 30 years of R&D in biotechnology, immunology and vaccinology.

  • ANGANY’s innovative approach is based on its ebioparticle™. This remodels the immune system, restoring immune tolerance and thus sustainably treating allergy, the source of allergic asthma.
  • ANGANY has developed an innovative, 3rd-generation plant production platform. This production system, based on plant transfection and transient expression, enables the efficient production of high-quality allergens and other sophisticated proteins for pharmaceutical use.

Although ANGANY focuses on allergic asthma, its biotechnology has considerable potential applications in fields as diverse as animal health, cancer, autoimmune diseases, endocrinology, infectious and orphan diseases.

Read more
angany-contact-locations-home

Contact

ANGANY inc.

ANGANY is a private clinical-stage biotechnology company pioneering a new approach to immunotherapy to overcome the challenge of allergic asthma.

Contact

Contact Form

Get in touch